Drug Profile
Oprozomib - Onyx Pharmaceuticals
Alternative Names: ONO-7058; ONX-012; ONX-0912; PR-047Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Onyx Pharmaceuticals
- Class Amides; Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules; Thiazoles
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple myeloma
Highest Development Phases
- Phase I/II Haematological malignancies; Multiple myeloma
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Australia (PO, Tablet)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Belgium (PO, Tablet)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Canada (PO, Tablet)